Edition:
India

Histogenics Corp (HSGX.OQ)

HSGX.OQ on NASDAQ Stock Exchange Capital Market

0.12USD
22 Mar 2019
Change (% chg)

$-0.00 (-3.23%)
Prev Close
$0.13
Open
$0.13
Day's High
$0.13
Day's Low
$0.12
Volume
319,674
Avg. Vol
1,499,718
52-wk High
$3.05
52-wk Low
$0.08

Latest Key Developments (Source: Significant Developments)

Histogenics Board Approves Further Restructuring Plan - SEC Filing
Saturday, 16 Mar 2019 

March 15 (Reuters) - Histogenics Corp ::HISTOGENICS CORP - ON MARCH 14, BOARD APPROVED A FURTHER RESTRUCTURING PLAN - SEC FILING.HISTOGENICS CORP - EXPECTS TO RECORD A ONE-TIME CHARGE FOR SEVERANCE AND RELATED EXPENSES OF APPROXIMATELY $2.2 MILLION BY END OF Q1 OF 2019.HISTOGENICS CORP - POSITIONS ELIMINATED TOGETHER REPRESENT ALL BUT ONE OF CO'S EMPLOYEES, INCLUDING CEO ADAM GRIDLEY, & COO STEPHEN KENNEDY.HISTOGENICS - GRIDLEY WILL RETAIN STATUTORY TITLES OF PRESIDENT, TREASURER & SECRETARY OF CO WHILE CONTINUING TO PROVIDE CONSULTING SERVICES TO CO.HISTOGENICS CORP - GRIDLEY AND KENNEDY'S EMPLOYMENT WITH COMPANY WILL TERMINATE EFFECTIVE MARCH 22, 2019.  Full Article

Histogenics Says John Johnson Notifies Board That He Would Resign As A Member Of Board
Wednesday, 6 Mar 2019 

March 5 (Reuters) - Histogenics Corp ::HISTOGENICS CORP - ON FEBRUARY 27, JOHN JOHNSON NOTIFIED BOARD THAT HE WOULD RESIGN AS A MEMBER OF BOARD EFFECTIVE FEBRUARY 27, 2019.HISTOGENICS CORP - BOARD HAS REDUCED NUMBER OF DIRECTORS FROM SEVEN TO SIX EFFECTIVE FEBRUARY 27, 2019.HISTOGENICS CORP - EFFECTIVE FEBRUARY 27, APPOINTED MR. BALTZELL AS CHAIRMAN OF COMPENSATION COMMITTEE OF BOARD.  Full Article

Histogenics Says Effective Jan 23, Board Approved Restructuring Plan Involving Headcount Reductions To Reduce Operating Costs
Friday, 25 Jan 2019 

Jan 24 (Reuters) - Histogenics Corp ::HISTOGENICS - EFFECTIVE JAN 23, BOARD APPROVED RESTRUCTURING PLAN INVOLVING HEADCOUNT REDUCTIONS TO REDUCE OPERATING COSTS.HISTOGENICS - RESTRUCTURING PLAN WAS TO REDUCE OPERATING COSTS FOLLOWING CO'S DECISION TO DISCONTINUE DEVELOPMENT OF NEOCART.HISTOGENICS - POSITIONS ELIMINATED TOGETHER REPRESENT ABOUT 65% OF CO'S WORKFORCE, INCLUDING CO'S CHIEF MEDICAL OFFICER AND CHIEF BUSINESS OFFICER.HISTOGENICS- EXPECTS TO SUBSTANTIALLY COMPLETE INITIAL RESTRUCTURING, RECORD ONE-TIME CHARGE FOR SEVERANCE, RELATED EXPENSES OF ABOUT $1.4 MILLION IN Q1.  Full Article

Histogenics Prices Public Offering Of Stock And Warrants
Friday, 5 Oct 2018 

Oct 5 (Reuters) - Histogenics Corp ::HISTOGENICS - PRICING OF OFFERING OF 26.2 MILLION SHARES, WARRANTS AT COMBINED PRICE OF $0.65 PER SHARE AND ACCOMPANYING WARRANT.HISTOGENICS CORPORATION ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS.  Full Article

Histogenics To Meet With FDA To Discuss Neocart Phase 3 Clinical Trial Data
Thursday, 27 Sep 2018 

Sept 26 (Reuters) - Histogenics Corp ::HISTOGENICS TO MEET WITH FDA TO DISCUSS NEOCART PHASE 3 CLINICAL TRIAL DATA AND POTENTIAL REGULATORY PATHWAY.HISTOGENICS CORP - FDA HAS GRANTED A TYPE C MEETING ON OCTOBER 30, 2018 TO DISCUSS TOP-LINE RESULTS FROM NEOCART PHASE 3 CLINICAL TRIAL.HISTOGENICS - EXPECTS TO PROVIDE UPDATE FOLLOWING MEETING WITH FDA IN EARLY NOV 2018, WITH MEETING MINUTES EXPECTED BY LATE NOV 2018 OR EARLY DEC 2018.HISTOGENICS - BELIEVES EXISTING CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND PROJECTED CASH NEEDS LATE INTO Q4 OF 2018.  Full Article

Histogenics Announces Top-Line Results From Phase 3 Clinical Trial Of NeoCart
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Histogenics Corp ::HISTOGENICS ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 CLINICAL TRIAL OF NEOCART® IN PATIENTS WITH KNEE CARTILAGE DAMAGE.PHASE 3 CLINICAL TRIAL OF NEOCART DID NOT MEET PRIMARY ENDPOINT.BOTH NEOCART AND MICROFRACTURE WERE WELL TOLERATED AND EXHIBITED STRONG SAFETY PROFILES IN TRIAL.IN PROCESS OF SCHEDULING MEETING WITH FDA TO PREPARE FOR POTENTIAL SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR NEOCART.NEOCART DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENTS ON DUAL THRESHOLD RESPONDER ANALYSIS SIX MONTHS AFTER TREATMENT.  Full Article

Histogenics Files For Mix Shelf Offering Of Up To $75 Mln
Saturday, 18 Aug 2018 

Aug 17 (Reuters) - Histogenics Corp ::HISTOGENICS CORP FILES FOR MIX SHELF OFFERING OF UP TO $75 MILLION - SEC FILING.  Full Article

Histogenics Corp Q2 Loss Per Share $0.13
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Histogenics Corp ::ANNOUNCES SECOND QUARTER 2018 FINANCIAL AND OPERATING RESULTS.Q2 LOSS PER SHARE $0.13.Q2 EARNINGS PER SHARE VIEW $-0.23 -- THOMSON REUTERS I/B/E/S.INITIATION OF PHASE 3 CLINICAL TRIAL IN JAPAN EXPECTED IN SECOND HALF OF 2018.AS OF JUNE 30, 2018, HISTOGENICS HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $8.8 MILLION.BELIEVES ITS CURRENT CASH POSITION WILL BE SUFFICIENT TO FUND ITS OPERATIONS INTO Q4 OF 2018.  Full Article

Histogenics Enters Equity Distribution Deal
Thursday, 15 Mar 2018 

March 15 (Reuters) - Histogenics Corp ::HISTOGENICS - ENTERED EQUITY DISTRIBUTION DEAL WHERE CO MAY SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE UP TO $10 MILLION VIA AGENT - SEC FILING.  Full Article

Histogenics And Medinet Enter Licensing Agreement For Commercialization Of NeoCart In Japan
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Medinet Co Ltd <2370.T>::HISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOCART FOR THE JAPANESE MARKET.HISTOGENICS - TRANSACTION TERMS INCLUDE A $10 MILLION UP-FRONT PAYMENT WITH A POTENTIAL OF $87 MILLION IN TOTAL MILESTONES, AND TIERED ROYALTIES ON SALES.HISTOGENICS - PLANS TO INITIATE PHASE 3 CLINICAL TRIAL IN JAPAN IN SECOND HALF OF 2018 WITH POTENTIAL COMMERCIALIZATION IN JAPAN IN 2021 FOR NEOCART.  Full Article